Skip to main content
. 2021 Nov 4;9(11):e002837. doi: 10.1136/jitc-2021-002837

Figure 2.

Figure 2

BXCL701 increases circulating inflammasome and Th1-related cytokines. (A) Heatmap showing average fold change of serum cytokine concentration of BXCL701-treated mice bearing Pan02 or mT3-2D tumors compared with PBS-treated controls. For the Pan02 sera, each value is the average of three triplicates. For the mT3-2D sera, each value is a single measurement of sera pooled from three to four mice. Th1 and inflammasome-related cytokines are bolded. (B) Serum concentration of inflammasome-related cytokines in mice bearing Pan02 tumors. Day 1 concentrations were compared with 0 timepoint. Day 7 and 14 concentrations were compared with vehicle. (n=3 mice/group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 calculated by ANOVA then Dunnett’s multiple comparison test, NM=not measured). (C) Serum concentration of Th1-related cytokines in mice bearing Pan02 tumors. Day 1 concentrations were compared with 0 timepoint. Day 7 and 14 concentrations were compared with vehicle. (n=3 mice/group, *p<0.05, ***p<0.001 calculated by ANOVA then Dunnett’s multiple comparison test, NM=not measured). ANOVA, analysis of variance; PBS, phosphate-buffered saline.